Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Amylin Pharmaceuticals
San Diego, California, United Statesen.wikipedia.org ↗
- Ownership
- Private
- Employees
- ~535
- Development stage
- Other
01
Overview
Amylin Pharmaceuticals developed and commercialized several first-in-class therapies for diabetes and metabolic disorders. Its lead products included pramlintide (Symlin) and exenatide-based drugs (Byetta and Bydureon). These drugs were approved for the treatment of type 2 diabetes; Symlin was also approved for type 1 diabetes as an adjunct to insulin. Byetta was the first GLP‑1 agonist approved in the US. At acquisition in 2012 by Bristol Myers Squibb (and subsequently AstraZeneca), these products were on market with established efficacy in glycemic control.
- Therapeutic areas
- Metabolic DisordersEndocrinology
- Modalities
- Small moleculePeptidesProtein
- Industry
- Biotech
02
Partnerships
Eli Lilly & Co. (historic development/commercialization partnership on exenatide)Johnson & Johnson/LifeScan division partnership on pramlintide developmentBristol Myers Squibb/AstraZeneca alliance post-acquisition
Beyond the preview
Go deeper on Amylin Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amylin Pharmaceuticals.